Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users

Psychopharmacology

Volumn 167, Issue 4, 2003, Pages 449-450

  Parrott, A C ^a   Buchanan, T ^b   Heffernan, T M ^c   Scholey, A ^c   Ling, J ^d   Rodgers, J ^e  

^a UNIVERSITY OF EAST LONDON   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c NORTHUMBRIA UNIVERSITY   (United Kingdom)

^d TEESSIDE UNIVERSITY   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

CLINICAL FEATURE; DOPAMINERGIC SYSTEM; HUMAN; LETTER; MEMORY DISORDER; MOTOR DYSFUNCTION; MYALGIA; NEUROTOXICITY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RECREATION; TIC; TREMOR;

EID: 0038236909     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1447-5     Document Type: Letter

References (13)

1. Caine DB, Langston JW, Martin WRW (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 317:246-248
2. Davis GC, Williams AC, Markey SP (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1:249-254
3. Kalant H (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can Med Assoc J 165:917-928
4. Langston JW, Ballard P, Tetrud JW, Irwin L (1983) Chronic Parkinsonism in humans due to a product of meperidine-analogue synthesis. Science 219:979-980
5. Langston JW, Ballard P (1984) Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and pathogenesis of Parkinson's disease. Can J Neurol Sci 11:160-165
6. McCann UD, Slate SO, Ricaurte GA (1996) Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). Drug Safety 15:107-115
7. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 139:261-268
8. Parrott AC, Buchanan T, Scholey AB, Heffernan TM, Ling J, Rodgers J (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy users. Hum Psychopharmacol 17:309-312
9. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetarnine in recreational users. Neuropsychopharmacology 1:273-277
10. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 297:2260-2263
11. Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151:19-24
12. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J (2003) Increased intensity of ecstasy and polydrug use in the more experienced ecstasy users. Addict Behav (in press)
13. Snyder SH (1984) Clues to aetiology from a toxin. Nature 311:514